Trimodality therapy (drug/hyperthermia/radiation) with BCNU or mitomycin C

Area of Science:

• Oncology
• Radiation Oncology
• Medical Physics

Background:

• Advanced local disease requires effective multimodality treatment strategies.
• Optimizing combinations of chemotherapy, hyperthermia, and radiation is crucial for enhanced curative potential.

Purpose of the Study:

• To evaluate the efficacy of combining BCNU (N,N'-bis(2-chloroethyl)-N-nitro-sourea) or mitomycin C with hyperthermia and radiation.
• To determine the dose-modifying factors and cell kill in oxic and hypoxic tumor subpopulations.

Main Methods:

• FSaIIC fibrosarcoma system used for growth delay experiments.
• Hoechst 33342 dye used to fractionate tumor cells into oxic and hypoxic subpopulations.
• Assessment of drug, hyperthermia, and radiation effects individually and in combination.

Main Results:

• BCNU plus hyperthermia yielded a radiation dose modifying factor (DMF) of 1.9 ± 0.3; mitomycin C plus hyperthermia yielded a DMF of 2.1 ± 0.4.
• BCNU was more toxic to oxic cells (3.1-fold), while mitomycin C was more toxic to hypoxic cells (3.5-fold).
• Trimodality treatment (drug-heat-radiation) achieved a 3-log kill in oxic cells with BCNU and a 3-log kill in hypoxic cells with mitomycin C.

Conclusions:

• Selected anticancer drugs combined with hyperthermia and radiation exhibit highly cytotoxic interactions.
• This multimodality approach significantly modifies radiation effects, offering potential for advanced local disease treatment.
• The sequence of drug administration relative to hyperthermia influences differential toxicity to oxic and hypoxic cells.